AU1824302A - Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases - Google Patents

Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

Info

Publication number
AU1824302A
AU1824302A AU1824302A AU1824302A AU1824302A AU 1824302 A AU1824302 A AU 1824302A AU 1824302 A AU1824302 A AU 1824302A AU 1824302 A AU1824302 A AU 1824302A AU 1824302 A AU1824302 A AU 1824302A
Authority
AU
Australia
Prior art keywords
antiprogestins
hormone
prophylaxis
treatment
dependent diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU1824302A
Other languages
English (en)
Inventor
Jens Hoffmann
Rosemarie Lichtner
Gerhard Siemeister
Martin Schneider
Ulrike Fuhrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU1824302A publication Critical patent/AU1824302A/xx
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU1824302A 2000-10-18 2001-10-17 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases Pending AU1824302A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24099800P 2000-10-18 2000-10-18
EP00250341 2000-10-18
PCT/EP2001/012005 WO2002032430A1 (en) 2000-10-18 2001-10-17 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

Publications (1)

Publication Number Publication Date
AU1824302A true AU1824302A (en) 2002-04-29

Family

ID=26072951

Family Applications (2)

Application Number Title Priority Date Filing Date
AU1824302A Pending AU1824302A (en) 2000-10-18 2001-10-17 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
AU2002218243A Ceased AU2002218243B2 (en) 2000-10-18 2001-10-17 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002218243A Ceased AU2002218243B2 (en) 2000-10-18 2001-10-17 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

Country Status (26)

Country Link
US (1) US7378406B2 (enExample)
EP (1) EP1328276B1 (enExample)
JP (2) JP2004511522A (enExample)
KR (1) KR100632908B1 (enExample)
CN (1) CN1512886A (enExample)
AT (1) ATE310522T1 (enExample)
AU (2) AU1824302A (enExample)
BG (1) BG107743A (enExample)
BR (1) BR0114665A (enExample)
CA (1) CA2423017C (enExample)
CY (1) CY1104981T1 (enExample)
CZ (1) CZ299942B6 (enExample)
DE (1) DE60115274T2 (enExample)
DK (1) DK1328276T3 (enExample)
EE (1) EE05259B1 (enExample)
ES (1) ES2253443T3 (enExample)
HR (1) HRP20030387A2 (enExample)
HU (1) HUP0301460A3 (enExample)
IL (2) IL154975A0 (enExample)
MX (1) MXPA03002954A (enExample)
NO (1) NO20031740L (enExample)
NZ (1) NZ538346A (enExample)
PL (1) PL360151A1 (enExample)
SI (1) SI1328276T1 (enExample)
SK (1) SK287124B6 (enExample)
WO (1) WO2002032430A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
US9517240B2 (en) * 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
WO2008128791A2 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
CN102906103A (zh) * 2010-03-22 2013-01-30 利普生物药剂公司 用于抗孕酮的非毒性递送的组合物和方法
MX363640B (es) 2012-05-31 2019-03-28 Repros Therapeutics Inc Formulaciones y metodos para la administracion vaginal de antiprogestinas.
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
CN1512886A (zh) 2004-07-14
DE60115274T2 (de) 2006-07-27
CZ299942B6 (cs) 2008-12-29
IL154975A (en) 2007-05-15
HUP0301460A2 (hu) 2003-10-28
CY1104981T1 (el) 2010-03-03
JP2004511522A (ja) 2004-04-15
SK287124B6 (sk) 2009-12-07
KR100632908B1 (ko) 2006-10-13
WO2002032430A1 (en) 2002-04-25
IL154975A0 (en) 2003-10-31
KR20030044007A (ko) 2003-06-02
NO20031740D0 (no) 2003-04-15
US20040048841A1 (en) 2004-03-11
BG107743A (bg) 2004-01-30
HRP20030387A2 (en) 2005-04-30
AU2002218243B2 (en) 2006-07-13
CA2423017C (en) 2009-01-06
ES2253443T3 (es) 2006-06-01
DE60115274D1 (de) 2005-12-29
MXPA03002954A (es) 2003-08-07
EP1328276A1 (en) 2003-07-23
DK1328276T3 (da) 2006-04-03
EE05259B1 (et) 2010-02-15
BR0114665A (pt) 2004-01-13
EP1328276B1 (en) 2005-11-23
CA2423017A1 (en) 2002-04-25
NZ538346A (en) 2007-03-30
JP2010077158A (ja) 2010-04-08
EE200300155A (et) 2003-08-15
SK4742003A3 (en) 2004-09-08
NO20031740L (no) 2003-06-17
ATE310522T1 (de) 2005-12-15
SI1328276T1 (sl) 2006-04-30
PL360151A1 (en) 2004-09-06
US7378406B2 (en) 2008-05-27
HUP0301460A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
AU1824302A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
EA200301022A1 (ru) Гормональная заместительная терапия
MXPA05012841A (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
YU30103A (sh) Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti
EE200300157A (et) Antiprogestiinide kasutamine apoptoosi esilekutsumiseks rakus
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
TW200733955A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
YU29903A (sh) Upotreba antiprogestina za indukciju apoptoze u ćeliji
UY27301A1 (es) Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata